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Abstract
A liposomal Muc1 mucin vaccine for treatment of adenocarcinomas was formulated by incorporating a synthetic Muc1
mucin-based lipopeptide and Lipid A into a DPPC/cholesterol bilayer. Vaccination of mice with the liposomal formulation
produced a peptide-specific immune response dependent on the cholesterol content. The response occurred at a threshold of
20^23 mol% cholesterol, and was optimal at cholesterol levels of v 30 mol%. To understand this cholesterol dependency, we
studied the effect of cholesterol on the liposomal bilayer and surface properties. Freeze-fracture electron microscopy showed
a unique surface texture that was codependent upon cholesterol (v 20 mol%) and lipopeptide content. Fluorescence
anisotropy measurements exhibited a significant decrease in the rotational motion of 1,6-diphenyl-1,3,5-hexatriene in
formulations containing s 20 mol% cholesterol and only in the presence of the lipopeptide. At 20 mol% cholesterol and with
lipopeptide, DSC showed a significant increase in the main phase transition of the DPPC bilayers, while Raman spectroscopy
indicated a more ordered arrangement of DPPC molecules compared to control liposomes containing DPPC/cholesterol
alone. Taken together, the data suggest the presence of lipopeptide-rich microdomains at and above a threshold of 20 mol%
cholesterol that may play a role in the induction of a peptide-specific immunological response. ß 2001 Published by
Elsevier Science B.V.
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1. Introduction
Cholesterol is the most studied sterol in animal
tissue and a signi¢cant component a¡ecting many
cellular and arti¢cial membrane properties. Choles-
terol has been included in many liposomal formula-
tions because of its e¡ects on the bilayer’s physical
parameters, as well as its biochemical interactions
with membrane constituents. Within the membrane,
cholesterol may associate with particular lipids or
proteins, regulate bilayer £uidity, and induce a con-
densing e¡ect which decreases membrane permeabil-
ity and increases rigidity [1].
Various biological responses have been attributed
to the association of cholesterol with other mem-
brane components and its a¡ects on the bilayer prop-
erties within liposomal and cellular membranes.
These have included the formation of lipid rafts [2],
an enhanced primary immune response [3], activation
of complement by liposomes [4], microviscosity
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changes a¡ecting antigen displacement and tumor
antigenicity [5,6] and in£uencing the functional prop-
erties of receptor proteins by formation of popula-
tions of high and low a⁄nity receptors [7]. Thus, the
presence of cholesterol-dependent microdomains and
their e¡ects on the membrane microviscosity can
have very signi¢cant physiological e¡ects.
Similar to the above examples, we have also noted
a cholesterol dependency on the immune responses
induced by a multilamellar liposomal vaccine formu-
lated for immunotherapeutic use against adenocarci-
nomas [8^13]. The vaccine was composed of DPPC/
DMPG/cholesterol and contained a synthetic, palmi-
tated human Muc1 mucin-based peptide (BLP25)
and Lipid A. In murine models, this formulation
induced antigen-speci¢c T-cell proliferation and cy-
tokine (interferon (IFN)-Q) secretion. Moreover, in
normal and human Muc1 transgenic mice, vaccina-
tion with the formulation protected against challenge
with syngeneic tumors transfected to express human
Muc1 and decreased the rate of growth of estab-
lished tumors. This formulation is currently in clin-
ical trials for lung cancer.
During preclinical studies, it was noted that the
biological e⁄cacy of this liposomal Muc1 vaccine
and a similar formulation lacking DMPG were de-
pendent on the amount of cholesterol included in the
liposomal formulation. To investigate the biophysical
basis of the latter observation, we have studied the
e¡ects of varying amounts of cholesterol on DPPC
bilayers in the presence and absence of Muc1 lipo-
peptide and Lipid A. We report evidence of changes
within the liposomal membrane, co-dependent upon
cholesterol and lipopeptide. We discuss these changes
and suggest that they are consistent with cholesterol/
lipopeptide-rich microdomains that may be impor-
tant for biological activity.
2. Materials and methods
2.1. Materials
The synthetic, palmitated 27-amino-acid Muc1
mucin-based lipopeptide (STAPPAHGVTSAPDTR-
PAPGSTAPP-K(Pal)G; referred to as Muc1 lipo-
peptide) and an irrelevant peptide (EAIQPG-
CIGGPKGLPGLPGP; referred to as BP-072) were
synthesized by Biomira (Edmonton, AL, Canada)
[12,13]. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC), Lipid A, cholesterol and sodium dodecyl
sulfate (SDS) were purchased from Avanti Polar Lip-
ids (Alabaster, AL). 1,6-Diphenyl-1,3,5-hexatriene
(DPH) was purchased from Molecular Probes (Eu-
gene, OR). Tri£uoroacetic acid was purchased from
Burdick and Jackson (Muskegon, MI). Absolute
ethanol (200 Proof) was U.S.P. grade and purchased
from Quantum Chemical Co. (Tuscola, IL). Sterile
0.9% normal saline solution (NSS) for injection
(U.S.P.) was purchased from Abbott Laboratories
(Chicago, IL). Sterile ¢ltration was performed using
Millex-GV, 0.22-Wm, 13-mm ¢lter units from Milli-
pore (Bedford, MA). Lyophilization was performed
in 2-ml (13-mm), U.S.P. grade, Type I glass vials
from Wheaton (Millville, NJ).
2.2. Preparation of liposomal Muc1 vaccine
A liposomal vaccine formulation for human mu-
cin-1 was prepared by incorporating a Muc1 mucin
lipopeptide into a DPPC/cholesterol bilayer. Lipid A
was included as an adjuvant. The appropriate stock
reagents of DPPC, cholesterol, Muc1 lipopeptide and
Lipid A were warmed to 55‡C in a water bath for
15^20 min. The required amount of each component
was added to a clean stoppered 2-ml glass vial, which
was vortexed brie£y (3 sU7 times) and returned to
the 55‡C water bath. Water (55‡C) was added to the
vial at a solvent/water ratio of 9:1 by volume and the
mixture vortexed brie£y as above. The mixture was
returned to the 55‡C water bath for about 15^20
min, vortexing (as above) twice during that period.
Samples were lyophilized using a Dura-Stop MP
shelf lyophilizer (FTS Systems, Stone Ridge, NY)
or a Model SC110 SpeedVac (Savant Instruments,
Holbrook, NY). Freeze-dried formulations were hy-
drated by addition of sterile NSS solution at 55‡C
with brief vortexing. After hydration, preparations
typically contained 20 mg/ml total bulk lipid (e.g.,
DPPC and cholesterol), 400 Wg/ml Muc1 lipopeptide
and 200 Wg/ml Lipid A.
2.3. Di¡erential scanning calorimetry (DSC)
DSC runs were performed on a CSC 4100 Multi-
cell Di¡erential Scanning Calorimeter (Calorimetry
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Sciences Corp., Provo, UT). Scan rates were run at
20‡C/h. NSS was used for baseline subtraction. Base-
line subtraction, correction for the thermal instru-
ment response and conversion to heat capacity (WJ/
‡C) as a function of temperature was performed us-
ing software supplied by CSC. The calorimetric data
were imported into Grams/32, v.5.0 (Galactic Indus-
tries Corp., Salem, NH) for baseline and o¡set cor-
rection, smoothing and plotting. Data were not
smoothed or only minimally smoothed by using a
Savitsky^Golay smoothing routine. This method
uses a convolution approach and performs a least
squares ¢t to a speci¢ed window. When data were
smoothed, a third-order polynomial and a window of
5^11 data points was typically employed.
2.4. Raman vibrational spectroscopy
Samples were placed in a glass capillary and spun
for 15 min in a microcapillary centrifuge to pack the
sample. The capillary was then sandwiched between
a heat exchanger and a peltier wafer (Melcor Elec-
tronic Products, Trenton, NJ). Temperature control
was via a Model TC2 Peltier Controller (Alpha Ome-
ga Instruments, Johnston, RI). Samples were run at
19‡C ( þ 0.2‡C). Raman spectra were recorded on a
Spex Ramalog-131 dispersive spectrometer equipped
with a Model 1403P motorized double monochrom-
eter and a Spex Spectrum One CCD detector (Spex
Industries, Edison, NJ). An Innova Model 90 argon
laser (Coherent, Santa Clara, CA) provided 150^200
mW of 514.5 nm laser excitation to the sample. At
150^200 mW no signi¢cant laser heating e¡ects were
observed. Typically, ten spectra were coadded using
a time constant of 16 s per collection. Spectral reso-
lution was at V1 cm31.
2.5. Sizing of the liposomal Muc1 vaccine
The liposomes were sized using an Accusizer 770
from Particle Sizing Systems (Santa Barbara, CA).
The binning was set at 128 diameter channels, the
threshold was set to 0.99 Wm and baselines were ob-
tained at the beginning of each session by using NSS.
Typically, 20^25 Wl of the hydrated preparation was
added to 50 ml of NSS in the round-bottom reservoir
of the Accusizer 770. NSS solution was used as the
diluent with continuous stirring.
2.6. Quanti¢cation of Muc1 lipopeptide by high-
pressure liquid chromatography (HPLC)
The samples were analyzed for total Muc1 lipo-
peptide and free Muc1 lipopeptide (supernatant after
centrifugation at 12 000Ug for 30 min at 4‡C). Prior
to injection samples were diluted 1:9 (total) or 1:1
(supernatants) by volume in a methanol solution
containing 30% (v/v) TFA and 2.5% (w/v) SDS. In-
jection (40 Wl = 1 Wg Muc1 lipopeptide) was made
onto a 25 cmU4.6 mm reverse-phase column (C4)
with a 300-Aî pore size (Vydac, Hesperia, CA). The
column was mounted in a Waters Model 625 LC
(Milford, MA) equipped with a Waters Variable
Wavelength Detector #486 set to 206 nm. Samples
were run using a gradient from 60% perchloric acid
(0.1 M, pH 2.5)/40% acetonitrile to 10% perchloric
acid (0.1 M, pH 2.5)/90% acetonitrile over 26 min.
Analysis was performed using Millennium software
(Waters, version 2.00) and based on a standard curve
generated over the range of 0.1^2.0 Wg Muc1 lipo-
peptide. Recovery was based on theoretical expec-
tations and incorporation was determined from
di¡erences between the total amount of Muc1 lipo-
peptide in the samples and the amount found in the
supernatants.
2.7. Analysis of components by thin-layer
chromatography (TLC)
Cholesterol and Lipid A concentration in the lipo-
somal Muc1 vaccine (i.e., hydrated product) was de-
termined by TLC. Samples were dissolved in chloro-
form/methanol (2:1) to form an optically clear
solution. This solution (2^100 Wl) was loaded by
capillary action onto 20U20-cm Whatman (Clifton,
NJ) silica gel plates (250 Wm thick, 19 channel pre-
scored, 60 A mesh size). Developing tanks were
equilibrated for 2 h at room temperature before add-
ing the plates. The system was run until the solvent
front was 2 cm from the top of the plate (about 30^
45 min). The following mobile phases were used at
the indicated volume to volume ratios: (1) chloro-
form/methanol/water/ammonium hydroxide (50:25:
4:2) for Lipid A detection; (2) hexane/diethyl ether/
formic acid (40:10:1) for cholesterol detection. Plates
were removed from the developing tanks and allowed
to air dry at room temperature then dipped for 5^10 s
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into a copper(II) sulfate reagent (0.63 M CuSO4 in
1.2 M H3PO4). After allowing excess reagent to drain
o¡ the plate, the spots were visualized by heating
the plate 5 or more minutes in a 160‡C oven. Sensi-
tivity was submicrogram (V0.25 Wg can be easily
seen).
2.8. Fluorescence anisotropy measurement
Liposomal preparations were ¢rst adjusted to
about 0.5 mM total bulk lipid (DPPC and cholester-
ol), then 1,6-diphenyl-1,3,5-hexatriene (DPH; 0.861
mM stock solution in ethanol) was added to a molar
ratio of total bulk lipid/DPH of approximately
500:1. Anisotropy measurements were performed us-
ing a PTI QM-1 Fluorometer (Photon Technology
International, Monmouth Jct., NJ) equipped with a
thermojacketed cell holder and L-format Glan^
Thompson polarizers. Temperature was accurate to
þ 1‡C. Readings were obtained at 22‡C, 41‡C and
50‡C using four di¡erent polarizer positions (VV,
VH, HH, HV). After samples were equilibrated at
the appropriate temperatures for 30 min, data was
collected using the FeliX Timebased Acquisition
Mode (PTI software) with excitation wavelength at
350 nm, emission wavelength at 430 nm and a dura-
tion of 60 s. The instrumental G-factor (V0.5) was
calculated each time, then using the mean emission
values, the £uorescence anisotropy (r) was calculated
as follows:
G  IHV=IHH; r  IVV3GIVH = IVV  2GIVH 
or
r  IVVIHH3IVHIHV=IVVIHH  2IVHIHV
2.9. Analysis of Pi content
Preparations of the liposomal Muc1 vaccine were
analyzed for phospholipid content using the ashing
method of Ames [14]. All samples and standards
were run in triplicate. Optical densities were obtained
at 820 nm using a Model UV-160U UV-Vis spectro-
photometer from Shimadzu Corp. (Tokyo, Japan).
Lots of Lipid A were also assayed to test their ex-
pected molar Pi content.
2.10. Electron microscopy of the liposomal
Muc1 vaccine
The morphology of liposomal Muc1 vaccines were
studied using freeze-fracture electron microscopy.
Samples were quick-frozen in liquid propane then
fractured and replicated on a Balzers (Liechtenstein)
freeze-etch unit, under a vacuum of better than
1U1036 mbar and a temperature of 3115‡C. Micro-
graphs of the replicas were obtained using a Philips
Model 300 electron microscope (The Netherlands).
2.11. Immunization of mice with the liposomal
Muc1 vaccine and IFN-Q secretion
C57BL/6 female mice (8^11 weeks old) from Ta-
conic Farms (Germantown, NY) were immunized
with the liposomal Muc1 vaccine. In four independ-
ent experiments, the vaccine was administered in two
50-Wl subcutaneous injections in the inguinal region.
In each experiment, nine mice per group were used.
After nine days, the mice were sacri¢ced by cervical
dislocation and lymph nodes and spleens were col-
lected. For each group of nine mice, lymphocytes
were isolated from three subsets, each representing
the pooling of three mouse spleens or inguinal lymph
nodes. These lymphocytes were restimulated in vitro
for 72 h with Muc1 lipopeptide, an irrelevant peptide
(BP-072), media, or concanavalin A (Con A). IFN-Q
secretion into the culture supernatants was measured
using an antibody-based microtiter plate capture as-
say. Europium-labeled streptavidin and time-resolved
£uorometry on a Model 1232 Del¢a Fluorometer
(Wallac, Turku, Finland) were used for quantitation
based on a standard curve of puri¢ed recombinant
IFN-Q (BD PharMingen, San Diego, CA).
3. Results and discussion
3.1. E¡ect of cholesterol content on biological activity
of the vaccine
The liposomal Muc1 vaccine was formulated with
varying amounts of cholesterol (0^50 mol%) to de-
termine the in£uence of cholesterol content on the
immune response. Cholesterol is miscible in DPPC
bilayers up to or greater than 50 mol% [15]. The
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vaccine was administered by bilateral subcutaneous
injection in the inguinal region. Lymphocytes were
isolated from pooled inguinal lymph nodes and
spleens (see Methods) and restimulated for 72 h in
vitro with Muc1 lipopeptide, an irrelevant peptide
(BP-072), media or Con A. The amount of IFN-Q
released in the culture supernatant was quantitated
and the mean and standard error of the data from
four separate experiments is shown in Fig. 1. IFN-Q
was not detected in control lymphocytes from mice
that received saline or when any of the isolated lym-
phocytes were restimulated with an irrelevant peptide
(data not shown), thus demonstrating that the re-
sponse was antigen-dependent and antigen-speci¢c.
In addition, lymphocytes from mice inoculated with
vaccine containing 0 or 10 mol% cholesterol did not
produce IFN-Q upon restimulation in vitro. A small
amount of IFN-Q was detected when the original
vaccine contained 20^23 mol% cholesterol, but an
optimal response occurred at cholesterol levels of
30^50 mol%. In control experiments (data not
shown), it was demonstrated that the IFN-Q response
was absolutely dependent upon inclusion of Lipid A
adjuvant in the liposomal vaccine. Fig. 1 demon-
strates that the release of IFN-Q, which varied with
the cholesterol content of the vaccine, was both anti-
gen-dependent and antigen-speci¢c.
3.2. Surface morphology
Freeze-fracture electron microscopy was used to
determine if the increase in the cholesterol content
of the liposomal Muc1 vaccine correlated with any
morphological di¡erences. Fig. 2 exhibits the elec-
tron micrographs of formulations prepared at 0, 20,
30 and 50 mol% cholesterol. At v20 mol% choles-
terol, a unique surface texture was observed when
the Muc1 lipopeptide was included in the formula-
tions (Fig. 2B^D). This surface appearance was not
seen in freeze-fracture studies of formulations at
0 mol% cholesterol (Fig. 2A) or 10 mol% cholesterol
(data not shown), nor was it seen in formulations at
a higher cholesterol content (50 mol%) when the
Muc1 lipopeptide was not included (Fig. 3B). In
the absence of cholesterol (Fig. 2A), one of the
vesicles exhibits the characteristic ripple phase of
DPPC bilayers. In addition, the absence of Lipid A
did not in£uence the liposomal surface texture (Fig.
3A). Hence, freeze-fracture electron microscopy dem-
onstrated that a unique surface structure existed and
was dependent upon a threshold of 20 mol% choles-
terol and the presence of the Muc1 lipopeptide. The
observed surface texture is likely a consequence of
the fracture plane jumping between bilayers in the
multilamellar vesicles. This could be caused by inho-
mogeneities within the plane of the bilayer and
would be consistent with the presence of lipid micro-
domains. Moreover, the unique surface texture ap-
peared to correlate with cholesterol levels required
for induction of an immune response.
3.3. Bilayer characteristics
The £uorophore 1,6-diphenyl-1,3,5-hexatriene
(DPH) was used to elucidate changes in the mem-
brane order in the Muc1 lipopeptide vaccine which
might shed light on the origin of the cholesterol-de-
pendent surface morphology and immune response.
Measurements were conducted at 22‡C, 41‡C and
50‡C. These temperature points are signi¢cant for
Fig. 1. IFN-Q response of mouse spleen and lymph node lym-
phocytes. The bars represent the means and standard error of
data from four independent experiments in which mice were
¢rst vaccinated with liposomal formulations (20 mg/ml total lip-
id consisting of DPPC and cholesterol) containing Muc1 lipo-
peptide and Lipid A and di¡erent amounts of cholesterol. After
9 days, spleen and lymph node lymphocytes were restimulated
in vitro with Muc1 lipopeptide and the amount of IFN-Q se-
creted was determined. No IFN-Q was detected in control mice
receiving saline (nd, not detected) or when any of the isolated
lymphocytes were restimulated in vitro with an irrelevant pep-
tide (BP-072, data not shown).
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hydrated DPPC bilayers in that they represent the
gel phase (22‡C), the ripple/liquid-crysalline phase
interface (41‡C) and the liquid-crysalline phase
(50‡C). In addition, the mouse body temperature is
approximately 41‡C. Fig. 4 compares the £uores-
cence anisotropy of DPH in DPPC liposomes con-
taining Muc1 lipopeptide (400 Wg/ml) and Lipid A
(200 Wg/ml) as a function of cholesterol content. At
22‡C, increasing amounts of cholesterol increased the
rotational motion of DPH independent of the pres-
ence of Lipid A and Muc1 lipopeptide (Fig. 4A).
This is expected since cholesterol addition should
break up well-ordered domains of DPPC in the gel
phase. However, liposomes containing the Muc1 lip-
opeptide exhibited a greater restriction on the rota-
tional motion of DPH than bilayers composed only
of DPPC/cholesterol. Studies at 37‡C were similar to
those at 22‡C (data not shown). Anisotropy measure-
ments obtained at 41‡C and 50‡C (Fig. 4B,C, respec-
tively) exhibited a threshold at V20 mol% cholester-
ol, above which a further decrease in the rotational
motion of DPH was evident only for those formula-
tions containing the Muc1 lipopeptide. At these tem-
peratures, increasing amounts of cholesterol should
Fig. 2. Freeze-fracture electron micrographs of liposomal formulations. The cholesterol content of all the liposomal formulations was
varied: 0 mol% (A); 20 mol% (B); 30 mol% (C); 50 mol% (D). All formulations contained 400 Wg/ml Muc1 lipopeptide and 200 Wg/
ml Lipid A. Freeze-fracture was performed on formulations warmed to room temperature. Bar = 250 nm.
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result in a uniform liquid-ordered phase [16,17]. Such
a state is seen most clearly in the control liposomes
at 50‡C (Fig. 4C, dotted line). The di¡erences in
anisotropy at all temperatures appeared to be depen-
dent on Muc1 lipopeptide and not Lipid A (see data
for 50 mol% cholesterol, Fig. 4A^C). These data may
suggest the formation of Muc1 lipopeptide-rich mi-
crodomains which are thermally labile at lower cho-
lesterol levels. Such microdomains may be immiscible
in a liquid-ordered bilayer, which would be promi-
nent at higher cholesterol levels (s 20 mol%). Alter-
natively, they could be stabilized by a preferential
uptake of cholesterol.
The dependence of the rotational motion of DPH
on Muc1 lipopeptide was further evaluated by com-
paring anisotropy data obtained at di¡erent concen-
trations of Muc1 lipopeptide over the range of 0^30
mol% cholesterol and in the absence of Lipid A. Fig.
5 shows data collected at 22‡C, 41‡C and 50‡C. At
all three temperatures an increase in Muc1 lipopep-
tide concentration resulted in a further decrease in
the rotational motion of the £uorophore. At 50‡C
and without Lipid A (Fig. 5C), 10 mol% cholesterol
compared to 20 mol% cholesterol in the presence of
Lipid A (Fig. 4C), was observed to further decrease
the rotational motion of DPH. A 20 mol% choles-
terol threshold was apparent at 41‡C at 400 and 1000
Wg/ml Muc1 lipopeptide (Fig. 5B). The higher choles-
Fig. 4. Fluorescence polarization anisotropy pro¢les as a func-
tion of cholesterol content. Solid lines denote liposomal formu-
lations containing 400 Wg/ml Muc1 lipopeptide and 200 Wg/ml
Lipid A (with exceptions as designated in ¢gures). Dotted lines
denote control liposomes prepared from DPPC/cholesterol.
22‡C (A); 41‡C (B); 50‡C (C).
Fig. 3. The e¡ect of Muc1 lipopeptide on the surface appear-
ance of liposomal formulations. All formulations contained 50
mol% cholesterol. (A) Liposomes containing 400 Wg/ml Muc1
lipopeptide and no Lipid A. (B) Liposomes containing 200 Wg/
ml Lipid A and no Muc1 lipopeptide. Freeze-fracture was per-
formed on formulations warmed to room temperature.
Bar = 250 nm.
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terol threshold at 50‡C in the presence of Lipid A
suggests that Lipid A has some role in ordering or
disordering the liposomal Muc1 vaccine bilayer.
Fluorescence anisotropy measurements were also
performed on a series of formulations prepared
from DPPC/cholesterol/Lipid A, but without Muc1
lipopeptide. At all temperatures studied these formu-
lations were similar to preparations containing
DPPC/cholesterol alone (data not shown). Hence,
Lipid A did not appear to a¡ect the rotational mo-
tion of DPH in the absence of the Muc1 lipopeptide.
Moreover, DPPC/cholesterol liposomes formulated
with lipopeptide alone still exhibited a decrease in
the rotational motion of DPH in conjunction with
increasing cholesterol content. These data suggest
that Lipid A is not associated with the putative mi-
crodomains and may exert a disordering e¡ect that
demands higher cholesterol content (20 vs. 10 mol%)
to overcome.
The calorimetric heating pro¢les of liposomal for-
mulations over the range of 0 to 30 mol% cholesterol
are shown in Fig. 6. At 0 mol% cholesterol, inclusion
of Muc1 lipopeptide and Lipid A signi¢cantly de-
creased the pretransition temperature and enthalpy
(38%) and moderately decreased the main phase
transition enthalpy (11%) of the DPPC bilayer.
Hence, these components destabilized the DPPC gel
phase and appeared to disrupt DPPC cooperative
units required for the pretransition. The lack of a
signi¢cant change in the band shape and full width
at half height (FWHH) of the main transition band
suggests a surface e¡ect. Higher levels of cholesterol
preclude the formation of a ripple phase and do not
exhibit a pretransition. At 20 mol% cholesterol, the
liposomal vaccine formulation exhibited a biphasic
Fig. 6. Di¡erential calorimetry heating pro¢les at varying
amounts of cholesterol. Solid lines denote control liposomes
prepared from DPPC/cholesterol. Dotted lines denote liposomal
formulations containing 400 Wg/ml Muc1 lipopeptide and 200
Wg/ml Lipid A. Heating scans were collected at 20‡C/h. No pre-
transition was observed at v 10 mol% cholesterol.
Fig. 5. Fluorescence polarization anisotropy pro¢les as a func-
tion of cholesterol and Muc1 lipopeptide content. All liposomal
formulations were prepared from DPPC/cholesterol without
Lipid A at four di¡erent concentrations of Muc1 lipopeptide:
0 Wg/ml (b) ; 100 Wg/ml (F) ; 400 Wg/ml (R) ; 1000 Wg/ml (8).
(A) 22‡C; (B) 41‡C; (C) 50‡C.
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transition and a signi¢cant increase in the main
phase transition enthalpy compared to control for-
mulations containing only DPPC/Cholesterol (4.2
kcal vs. 2 kcal). The peak shape was biphasic with
a sharp lower-temperature component and a broader
higher-temperature component. The existence of the
sharp and broad components would be consistent
with a lateral phase separation due to cholesterol-
free and cholesterol-rich domains, respectively [18].
The e¡ect at 20 mol% cholesterol was equivalent to
a reduction in cholesterol available to mix with the
bulk DPPC. Above cholesterol levels of 30 mol%,
di¡erences could not be observed due to the broad
transition bands. Hence, DSC, like £uorescence ani-
sotropy and freeze-fracture EM, exhibited a thresh-
old e¡ect of 20 mol% cholesterol. Such an e¡ect is
again consistent with a preferred association between
cholesterol and the Muc1 lipopeptide, but does not
address possible contributions from DPPC and/or
Lipid A.
Fig. 7 shows the DSC heating pro¢les for lipo-
somal formulations containing Lipid A (200 Wg/ml)
in the absence of lipopeptide over the 0^30 mol%
cholesterol range. At 0 mol% cholesterol, Lipid A
lowered the pretransition temperature of DPPC bi-
layers and slightly diminished the main phase tran-
sition temperature and enthalpy. Interestingly, with-
out the lipopeptide, the pretransition enthalpy is not
signi¢cantly reduced (compare to Fig. 6). Lipid A
appears to prefer the ripple or liquid-crysalline phase
over the gel phase, but does not disrupt DPPC co-
operative units required to exhibit a ripple phase. At
10 mol% cholesterol, inclusion of Lipid A resulted in
a signi¢cant decrease in the main phase transition
temperature compared to control liposomes, while
above 10 mol% cholesterol, only small decreases in
the overall main transition phase enthalpies were ob-
served. Such an e¡ect suggests that in the presence of
cholesterol, Lipid A further promotes DPPC bilayer
disorder. At low cholesterol levels, inhomogeneities
in the bilayer packing arrangement may not accom-
modate Lipid A. Hence, formation of a liquid-crys-
talline phase is promoted. These data may also ex-
plain why £uorescence anisotropy exhibited a higher
cholesterol threshold requirement to decrease the ro-
tational motion of DPH in the presence of Lipid A
(Fig. 4C) compared to its absence (Fig. 5C). More-
over, Fig. 7 does not display the biphasic transition
seen with Muc1 lipopeptide at 20 mol% cholesterol
(Fig. 6) suggesting that such an e¡ect is dependent
on Muc1 lipopeptide or Muc1 lipopeptide/Lipid A
and not Lipid A alone. It also suggests that Lipid
A/cholesterol domains do not form and that without
the presence of lipopeptide, cholesterol is free to fully
interact with the bulk DPPC lipid.
Raman vibrational spectroscopy is particularly
sensitive to changes in the intramolecular and inter-
molecular packing characteristics of the phospholipid
bilayer. If lipid microdomains existed due to Muc1
lipopeptide/cholesterol associations, the presence of a
more ordered arrangement of DPPC would support
the hypothesis that some cholesterol is sequestered
from the bulk DPPC molecules. Fig. 8A shows the
Raman spectra obtained at 19‡C in the C^H stretch-
ing region of DPPC bilayers at 20 mol% cholesterol.
A signi¢cant di¡erence was observed in the presence
of Muc1 lipopeptide and Lipid A. Fig. 8B,C show
Fig. 7. Di¡erential calorimetry heating pro¢les at varying
amounts of cholesterol (Lipid A contribution). Solid lines de-
note control liposomes prepared from DPPC/cholesterol. Dot-
ted lines denote liposomal formulations containing 200 Wg/ml
Lipid A and no Muc1 lipopeptide. Heating scans were collected
at 20‡C/h.
BBAMEM 78148 31-8-01
M.M. Batenjany et al. / Biochimica et Biophysica Acta 1514 (2001) 280^290288
the calculated intramolecular (I2930/I2880) and inter-
molecular (I2850/I2880) order parameters [19,20] over
the range of 0^30 mol% cholesterol. The DPPC bi-
layers were more ordered at 20 mol% cholesterol
when the Muc1 lipopeptide/Lipid A components
were included. These data are consistent with an ef-
fective decrease in the amount of cholesterol avail-
able to the bulk DPPC lipid. Due to the large
amount of DPPC present, it remains unclear if
DPPC is a component of the putative complex.
4. Conclusions
This study has demonstrated that a peptide-specif-
ic cellular immune response (IFN-Q production) in
mice inoculated with a Muc1 mucin-based liposomal
vaccine was a¡ected by the cholesterol content of the
liposomes. Taken together, our results support the
formation of Muc1 lipopeptide/cholesterol microdo-
mains analogous to lipid rafts described by other
workers [2,21]. Furthermore, they are consistent
with liposomal studies showing a link between cho-
lesterol level and both bilayer microviscosity and the
magnitude of the primary immune response [3].
Lipid rafts are membrane microdomains formed
by the preferential packing of membrane compo-
nents. For sphingolipid/cholesterol rafts, Simons
and Ikonen [2] described a model involving a lateral
association due to weak interactions between the car-
bohydrate headgroups of glycosphingolipids, with
cholesterol as a spacer to ¢ll the voids between the
associated sphingolipids. The DSC and Raman vi-
brational spectroscopy data shown in Figs. 6 and 8
suggest that in the presence of lipopeptide some cho-
lesterol was sequestered from the bulk lipid. Hence,
this would be consistent with lipopeptide/cholesterol
microdomains. The signi¢cant but small changes ob-
served in Fig. 8 could be analogous to reports that
suggest individual lipids may move in and out of the
rafts, which make a sphingolipid-cholesterol cluster
di⁄cult to detect spectroscopically [22,23]. Yuan and
Johnston [21] used atomic force microscopy to ob-
serve lipid raft formation in monolayers composed of
physiologically relevant amounts of ganglioside GM1
(a receptor for the cholera toxin) in a DPPC/cho-
lesterol system and found GM1-rich submicron
domains (V100 nm) within the surrounding liquid-
ordered phase (sV30 mol% cholesterol). Interest-
ingly, the freeze fracture data shown in Figs. 2 and 3
exhibits a lipopeptide-dependent surface texture (at
v 20 mol% cholesterol), which is also of submicron
dimension. Finally, although sphingomyelin is not
present, the amide-linked, palmitated Muc1 mucin
peptide may preferentially associate with cholesterol.
A signi¢cant preference for the amide-linkage, sphin-
gomyelins and especially saturated acyl chains was
found to be important for association with cholester-
ol [24]. In addition, prenylated proteins were ex-
cluded, while proteins covalently linked to saturated
acyl chains were found to incorporate into the cho-
lesterol-rich domains [25].
We hypothesize that a role for the putative Muc1
lipopeptide/cholesterol microdomains may be to in-
£uence antigen uptake and processing by the antigen
Fig. 8. Raman spectra of control and liposomal vaccine formu-
lations. (A) Comparison of a DPPC/cholesterol control lipo-
some to a vaccine formulation containing 400 Wg/ml Muc1 lipo-
peptide and 200 Wg/ml Lipid A, both at 20 mol% cholesterol.
(B,C) Calculated Raman order parameters for control and vac-
cine formulations over the range of 0^30 mol% cholesterol. See
text for explanation of the Raman order parameters. Control
(solid lines); Muc1 lipopeptide vaccine (dashed lines).
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presenting cells (APC). In this regard, it is notewor-
thy that Mayor et al. [26] observed a cholesterol-de-
pendent endocytic sorting of glycosylphosphatidyl-
inositol anchored proteins and suggested the
involvement of specialized lipid domains or rafts in
endocytic sorting. Our observation of a 30 mol%
cholesterol threshold for optimal immune response
may be due to constraints imposed by the APC
membrane composition. For example, typical mam-
malian cell membranes contain V20^30 mol% cho-
lesterol. Hence, a higher amount may be required to
e¡ect a multimeric aggregation and/or e¡ect antigen
uptake or processing by the APC. We note that the
formation of these putative microdomains alone was
not su⁄cient for induction of a strong immune re-
sponse. Lipid A, whose contribution (if any) to the
formation of microdomains appeared to be minor,
nevertheless was required for a vigorous immune re-
sponse. Its role may depend on promoting matura-
tion of APCs.
We are currently pursuing studies to test if the
cholesterol dependency of the immune response to
the vaccine correlates with di¡erences in antigen up-
take and processing or alternatively, di¡erences in
liposome tra⁄cking to the lymph nodes and spleen.
Clearly, the presence of speci¢c microdomains could
in£uence both. To our knowledge, this is the ¢rst
report suggesting biologically active lipid raft-like
structures not involving sphingolipid or ganglioside
components in cholesterol rich liposomes.
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